Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
Thea Asselt (),
Bram Ramaekers,
Isaac Corro Ramos,
Manuela Joore,
Maiwenn Al,
Ivonne Lesman-Leegte,
Maarten Postma,
Pepijn Vemer and
Talitha Feenstra
Additional contact information
Thea Asselt: University of Groningen
Bram Ramaekers: Maastricht University
Isaac Corro Ramos: Erasmus University
Manuela Joore: Maastricht University
Maiwenn Al: Erasmus University
Ivonne Lesman-Leegte: University of Groningen
Maarten Postma: University of Groningen
Pepijn Vemer: University of Groningen
Talitha Feenstra: University of Groningen
PharmacoEconomics, 2018, vol. 36, issue 1, No 11, 105-113
Abstract:
Abstract Background The costs of performing research are an important input in value of information (VOI) analyses but are difficult to assess. Objective The aim of this study was to investigate the costs of research, serving two purposes: (1) estimating research costs for use in VOI analyses; and (2) developing a costing tool to support reviewers of grant proposals in assessing whether the proposed budget is realistic. Methods For granted study proposals from the Netherlands Organization for Health Research and Development (ZonMw), type of study, potential cost drivers, proposed budget, and general characteristics were extracted. Regression analysis was conducted in an attempt to generate a ‘predicted budget’ for certain combinations of cost drivers, for implementation in the costing tool. Results Of 133 drug-related research grant proposals, 74 were included for complete data extraction. Because an association between cost drivers and budgets was not confirmed, we could not generate a predicted budget based on regression analysis, but only historic reference budgets given certain study characteristics. The costing tool was designed accordingly, i.e. with given selection criteria the tool returns the range of budgets in comparable studies. This range can be used in VOI analysis to estimate whether the expected net benefit of sampling will be positive to decide upon the net value of future research. Conclusion The absence of association between study characteristics and budgets may indicate inconsistencies in the budgeting or granting process. Nonetheless, the tool generates useful information on historical budgets, and the option to formally relate VOI to budgets. To our knowledge, this is the first attempt at creating such a tool, which can be complemented with new studies being granted, enlarging the underlying database and keeping estimates up to date.
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
http://link.springer.com/10.1007/s40273-017-0572-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0572-7
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273
DOI: 10.1007/s40273-017-0572-7
Access Statistics for this article
PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell
More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().